Biome Grow Past Earnings Performance
Past criteria checks 0/6
Biome Grow has been growing earnings at an average annual rate of 4.3%, while the Pharmaceuticals industry saw earnings growing at 31.5% annually. Revenues have been declining at an average rate of 21.8% per year.
Key information
4.3%
Earnings growth rate
5.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | -21.8% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Biome Grow makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -2 | 1 | 0 |
| 30 Jun 23 | 0 | -3 | 1 | 0 |
| 31 Mar 23 | 0 | -7 | 1 | 0 |
| 31 Dec 22 | 0 | -11 | 1 | 0 |
| 30 Sep 22 | 0 | -10 | 1 | 0 |
| 30 Jun 22 | 0 | -13 | 1 | 0 |
| 31 Mar 22 | 0 | -21 | 1 | 0 |
| 31 Dec 21 | 0 | 0 | 1 | 0 |
| 30 Sep 21 | 0 | 6 | 1 | 0 |
| 30 Jun 21 | 0 | 5 | 3 | 0 |
| 31 Mar 21 | 0 | 17 | 4 | 0 |
| 31 Dec 20 | 0 | -2 | 4 | 0 |
| 30 Sep 20 | 0 | -12 | 4 | 0 |
| 30 Jun 20 | -2 | -9 | 3 | 0 |
| 31 Mar 20 | 0 | -9 | 4 | 0 |
| 31 Dec 19 | 0 | -9 | 4 | 0 |
| 30 Sep 19 | 0 | -10 | 7 | 0 |
| 30 Jun 19 | 2 | -9 | 7 | 0 |
| 31 Mar 19 | 0 | -9 | 6 | 0 |
| 31 Dec 18 | 0 | -9 | 5 | 0 |
| 30 Sep 18 | 0 | -3 | 3 | 0 |
| 30 Jun 18 | 0 | -2 | 2 | 0 |
| 31 Mar 18 | 0 | -1 | 1 | 0 |
| 31 Dec 17 | 0 | -1 | 1 | 0 |
Quality Earnings: BIO is currently unprofitable.
Growing Profit Margin: BIO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIO is unprofitable, but has reduced losses over the past 5 years at a rate of 4.3% per year.
Accelerating Growth: Unable to compare BIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).
Return on Equity
High ROE: BIO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.